Condition
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 3 (1)
Trial Status
Enrolling By Invitation1
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07728318Not ApplicableNot Yet RecruitingPrimary
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
NCT06858878Phase 3Active Not RecruitingPrimary
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT07209527Early Phase 1Enrolling By Invitation
Truway Diagnostic Tools in Primary Care
Showing all 3 trials